Active Ingredient(s): Tositumomab
FDA Approved: * June 27, 2003
Pharm Company: * CORIXA
Category: Cancer

Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell.[1] It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma.[1] It is classified as a IgG2a lambda antibody.[1][2] The drug combination was developed by Corixa which was purchased by GlaxoSmithKline in... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Bexxar Kit
NDC: 0007-3260
Glaxosmithkline LLC